Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celgosivir + Zidovudine in HIV
NCT00000791Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of celgosivir in human immunodeficiency virus infection (HIV) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Safety and Tolerability at 24 weeks and Anti-HIV Activity at 24 weeks. Status: completed.
02
Drugs
celgosivir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00000791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000791.